Hanmi Seeks To Swim In 'Blue Oceans' As It Expands Globally
Undruggable Targets, Rare Diseases, New Modalities
Executive Summary
At a recent forum in Seoul, an executive of Hanmi Pharmaceuticals, whose novel neutropenia drug has just received a US green light, shares why it is crucial to create "blue oceans" through global innovative drug development and how the Korean firm plans to challenge these markets.
You may also be interested in...
Spectrum Sees Potential Path For Poziotinib In NSCLC Despite Expected CRL
The CRL follows a negative FDA advisory committee vote in September. The company will lay off three-quarters of its R&D force, but sees potential to partner or sell the asset.
Asia Deal Watch: Busy Eikon Partners With Impact On Selective PARP1 Inhibitors
Yuhan and J INTS BIO and Betta and C4 sign deals centered on lung cancer candidates. Viatris’s Japanese affiliate gets in-country rights to InDex’s Phase III ulcerative colitis candidate.
Kanaph CEO On Surviving The Biotech Funding 'Barley Hump'
The CEO of Korean bioventure Kanaph Therapeutics, Byoung Chul Lee, talks to Scrip about the difficulties such companies are going through amid generally weak investor sentiment, as well as the company's own financing and R&D plans.